Lycopene Improves Bone Quality and Regulates AGE/RAGE/NF-кB Signaling Pathway in High-Fat Diet-Induced Obese Mice

Oxid Med Cell Longev. 2022 Feb 17:2022:3697067. doi: 10.1155/2022/3697067. eCollection 2022.

Abstract

Objective: This study was aimed at examining the effects of lycopene on bone metabolism in high-fat diet (HFD)- induced obese mice and to identify the potential underlying mechanisms.

Methods: Mice were fed a HFD for 12 weeks and then continue with or without lycopene intervention (15 mg/kg) for additional 10 weeks. The effects of lycopene on blood glucose and lipid metabolism, as well as serum levels of total antioxidant capacity (T-AOC), superoxide dismutase (SOD), and malondialdehyde (MDA) were determined by biochemical assays. Bone histomorphological features and osteoclast activity were assessed by hematoxylin/eosin and tartrate-resistant acid phosphatase staining. Bone microstructure at the proximal tibial metaphysis and diaphysis was determined by microcomputed tomography. Tibial biomechanical strength and material profiles were measured by a three-point bending assay and Fourier transform infrared spectroscopy. Protein expressions involved in the AGE/RAGE/NF-кB signaling pathway were determined by western blot and/or immunohistochemical staining.

Results: Lycopene consumption reduced body weight gain and improved blood glucose and lipid metabolism in HFD-induced obese mice. In addition, lycopene treatment preserved bone biomechanical strength, material profiles, and microarchitecture in obese mice. Moreover, these alterations were associated with an increase in serum levels of T-AOC and SOD, and a decline in serum levels of MDA, as well as a reduction of AGEs, RAGE, cathepsin K, and p-NF-кBp65 and NF-кBp65 expressions in the femurs and tibias of obese mice.

Conclusion: Lycopene may improve bone quality through its antioxidant properties, which may be linked with the regulation of the AGE/RAGE/NF-кB signaling pathway in obese mice. These results suggest that lycopene consumption may be beneficial for the management of obesity-induced osteoporosis.

MeSH terms

  • Animals
  • Antioxidants / administration & dosage
  • Antioxidants / pharmacology*
  • Blood Glucose / drug effects
  • Bone and Bones / drug effects*
  • Bone and Bones / metabolism
  • Bone and Bones / pathology
  • Cathepsin K / metabolism
  • Diet, High-Fat / adverse effects
  • Femur / drug effects
  • Femur / metabolism
  • Femur / pathology
  • Glycation End Products, Advanced / metabolism*
  • Lipid Metabolism / drug effects
  • Lycopene / administration & dosage
  • Lycopene / pharmacology*
  • Mice
  • NF-kappa B / metabolism*
  • Obesity / drug therapy*
  • Obesity / etiology
  • Obesity / metabolism
  • Obesity / pathology
  • Oxidative Stress / drug effects
  • Receptor for Advanced Glycation End Products / metabolism*
  • Signal Transduction / drug effects
  • Tibia / drug effects
  • Tibia / metabolism
  • Tibia / pathology

Substances

  • Antioxidants
  • Blood Glucose
  • Glycation End Products, Advanced
  • NF-kappa B
  • Receptor for Advanced Glycation End Products
  • Cathepsin K
  • Lycopene